PREVENT COVID 101 Study
STUDY BASICS
Are you a healthy individual between 18-55 years of age who is fully vaccinated (does not include booster vaccine) for SARS-CoV-2? You may be able to participate in a research study to evaluate the safety of a nasal spray that is being studied for the prevention of SARS-CoV2 (the virus that causes COVID-19). Study participation includes 7 visits over 6-8 weeks. Compensation is provided.
IRB: STUDY21100009
- Phase I Clinical Trial of a Q GRFT Nasal SprayMEET THE RESEARCHER

Katherine Bunge
Katherine Bunge, MD, MPH, is an Assistant Professor, Department of Obstetrics, Gynecology & Reproductive Sciences at Magee-Womens Hospital of UPMC. Dr. Bunge's research interests include investigating the safety of vaginal microbicide products, expanding contraceptive options in HIV prevention trials, and developing alternative microbicide formulations. Dr. Bunge earned her medical and masters degrees from the Johns Hopkins School of Medicine, completed her residency at Northwestern Memorial Hospital, and performed her fellowship at Magee-Womens Hospital of UPMC.